CA-CHARGEPOINT-HOLDINGS
5.10.2022 09:01:38 CEST | Business Wire | Press release
ChargePoint Holdings, Inc. (NYSE: CHPT), a leading electric vehicle (EV) charging network, today announced the launch of the CP6000, ChargePoint’s most flexible and serviceable global AC EV charging solution now available for vehicles of all types and sizes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005038/en/
(Photo: Business Wire)
Designed for the needs of the European market, the CP6000 is a complete charging solution for businesses and fleets that want to confidently and efficiently prepare for the future of electric mobility. Seamlessly integrating network software, station hardware and customer support, the CP6000 is designed to prepare businesses of all kinds across the globe for the next wave of EV adoption. The CP6000 is designed for scalability, flexibility, reliability, and a best-in-class driver experience, and offers reliable AC charging for 1 or 3 phase power at an adaptable output of 3.7 to 22kw per port.
“ChargePoint’s mission is to make the transition to electric mobility simple. As the result of ChargePoint’s experience shaping the charging industry over the past 15 years, we understand what is critical to station owners and drivers, including effortless charging experiences, scalable design, quality products and excellent service,” stated ChargePoint Chief Product Officer, Bill Loewenthal. “EV charging needs are universal, even if what and how we drive varies by geography. The CP6000 has been designed across our R&D facilities in North America and Europe to cater to the charging needs of businesses, fleets and EV drivers. Built on our decade-plus of experience serving EV drivers and all types of organisations, CP6000 has what businesses need to be part of the future of electric mobility.”
Superior driver experience
Whether charging is for employees, customers, visitors or a fleet, the driver is at the centre of it all, which is why the driver is at the centre of the CP6000 design. The top-rated ChargePoint app has over 200,000 active places to charge on its network globally, as well an additional 355,000 public places to charge through roaming integrations with other major networks. ChargePoint driver support is available in multiple languages, ensuring drivers across Europe receive the best experience possible. The addition of the CP6000 to ChargePoint’s network ensures drivers are easily able to find, use and pay for the charge they need, in the language and currency they prefer.
“The new CP6000 series is a great addition to an already strong contingent of reliable, software driven hardware we offer our clients,” stated Bruce Galliford, CEO at RAW Charging, one of the first customers to receive the new technology. “When ChargePoint expanded to Europe, we saw a company with the longevity, customer base, engineering prowess and experience to be a fit with our vision. Leaving the technology to ChargePoint, we can focus on deployment. We have more projects coming for Aviva Investors, Greene King, McArthurGlen and other customers. We’re currently planning strategic expansion across Europe working with organisations that have a portfolio of sites across the continent. This year we’ll be putting in four new sites per working day, and when you’re doing that, you want it to work flexibly and at scale.”
Part of ChargePoint's unified software platform
The CP6000 works seamlessly with ChargePoint’s software platform, which offers real-time visibility into revenue, energy costs and driver details, complete control over pricing and driver access, and actionable reporting with over 35 pre-built charts and reports. ChargePoint’s software also includes robust power management tools to automatically reduce energy costs, on-station video messages, and over 40 turnkey API integrations. The CP6000 is also fully compliant with Open Charge Point Protocol (OCPP) 2.01, the latest version of the open standard. Together, these features make it easy for customers to manage their charging program, reduce costs, improve utilisation, and prepare for the future.
Built for the future of electrification
ChargePoint believes demand for EV charging is poised for rapid growth. The CP6000 series’ modular design and forward-thinking technology supports flexible configurations and easy upgrades, making it the robust solution for scaling EV charging availability and maximising station value. It can be customised into dozens of configurations for multiple use cases or regions, offering options on sockets, cable management, branding, display, shuttering and more. This modularity allows the CP6000 to more easily support field replacements and service, while also offering advanced sensors for enhanced diagnostics and support.
The CP6000 has also been designed to operate on Europe's variety of power grids and regulations. For example, the CP6000 meets the UK government's requirements for contactless payment capabilities for all AC stations of 7.1kW and above.
The CP6000 is now available to order across dozens of ChargePoint operating countries. To learn more about deploying the CP6000 across your business, contact your ChargePoint sales representative or distributor.
About ChargePoint
ChargePoint is creating a new fueling network to move people and goods on electricity. Since 2007, ChargePoint has been committed to making it easy for businesses and drivers to go electric with one of the largest EV charging networks and a comprehensive portfolio of charging solutions available today. The ChargePoint cloud-based subscription platform and software-defined charging hardware are designed to include options for every charging scenario from home and multifamily to workplace, parking, hospitality, retail and transport fleets of all types. Today, one ChargePoint account provides access to hundreds of thousands of places to charge in North America and Europe. To date, more than 133 million charging sessions have been delivered, with drivers plugging into the ChargePoint network on average every second. For more information, visit the ChargePoint pressroom, the ChargePoint Investor Relations site, or contact ChargePoint’s North American or European press offices or Investor Relations.
CHPT-IR
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005038/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom